Sign in
MRSN Stock Price, Chart, Stats & News
Mersana Therapeutics, Inc.
Save
Mersana Therapeutics, Inc. (MRSN) does not currently pay a dividend.
145.36M
Market cap
–
Current P/E
–
Forward P/E
MRSN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 99.14% |
Operating margin | -203.06% |
Pretax margin | -211.21% |
Net margin | -211.21% |
Effective tax rate | – |
ROA | -111.80% |
ROE | 183.15% |
D/E | -0.04x |
Interest coverage ratio | -24.54x |
MRSN valuation
P/E | – |
P/S | 4.38x |
P/B | -2.44x |
P/CF | -1.95x |
P/FCF | -1.95x |
P/OCF | -1.95x |
PEG | -0.37x |
EV multiple | -3.01x |
About
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering novel antibody-drug conjugates (ADCs) for cancer patients with pressing unmet medical needs. Their flagship product candidate, XMT-1592, a Dolasynthen ADC engineered to target NaPi2b-expressing tumor cells, is presently undergoing Phase I clinical evaluation for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company's development pipeline also includes XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate, and XMT-2056, an Immunosynthen development candidate.
Similar securities
Based on sector and market capitalization
Report issue